MedinCell S.A.
MDCLF · OTC
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $14 | $16 | $9 | $4 |
| % Growth | -15.4% | 70.7% | 150.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $16 | $9 | $3 |
| % Margin | 0% | 100% | 100% | 91.3% |
| R&D Expenses | $15 | $14 | $10 | $10 |
| G&A Expenses | $0 | $6 | $5 | $5 |
| SG&A Expenses | $9 | $7 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $2 | $2 | $1 |
| Other Operating Expenses | $0 | -$2 | -$0 | $0 |
| Operating Expenses | $23 | $19 | $17 | $16 |
| Operating Income | -$11 | -$3 | -$8 | -$12 |
| % Margin | -78.8% | -20.6% | -79.8% | -318.6% |
| Other Income/Exp. Net | -$11 | -$1 | -$7 | -$5 |
| Pre-Tax Income | -$22 | -$4 | -$14 | -$17 |
| Tax Expense | -$3 | $0 | $0 | $0 |
| Net Income | -$19 | -$4 | -$15 | -$17 |
| % Margin | -138.5% | -24% | -154.4% | -448.3% |
| EPS | -0.57 | -0.13 | -0.5 | -0.58 |
| % Growth | -338.5% | 74% | 13.8% | – |
| EPS Diluted | -0.57 | -0.13 | -0.5 | -0.58 |
| Weighted Avg Shares Out | 33 | 32 | 29 | 29 |
| Weighted Avg Shares Out Dil | 33 | 32 | 29 | 29 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $1 |
| Interest Expense | $3 | $3 | $2 | $4 |
| Depreciation & Amortization | $1 | $2 | $0 | $0 |
| EBITDA | -$17 | -$4 | -$7 | -$12 |
| % Margin | -127.5% | -24.5% | -76.9% | -306.8% |